FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:801-802 March 18, 1993 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Type IV glycogen storage disease results in progressive destruction of the liver and other vital organs, including the heart. This disease, caused by a deficiency of the branching enzyme -1,4-glucan-1,4-glucan 6-transferase, results in the accumulation of a damaging amylopectin-like polysaccharide in these organs. In this issue of the Journal, Starzl et al.¹ extend a previous report² that liver transplantation in patients with type IV glycogen storage disease reduced the deposition of amylopectin in the heart. Furthermore, liver transplantation in a patient with Gaucher's disease resulted in the disappearance of the toxic glucocerebroside from involved tissue¹.

The authors show that . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Li, H. S., Ligons, D. L., Rose, N. R., Guler, M. L. (2008). Genetic Differences in Bone Marrow-Derived Lymphoid Lineages Control Susceptibility to Experimental Autoimmune Myocarditis. J. Immunol. 180: 7480-7484 [Abstract] [Full Text]